Lpath Inc (LPTN.OQ)

LPTN.OQ on NASDAQ Stock Exchange Capital Market

0.21USD
11:48am EDT
Change (% chg)

$0.01 (+3.51%)
Prev Close
$0.20
Open
$0.23
Day's High
$0.23
Day's Low
$0.21
Volume
56,142
Avg. Vol
124,113
52-wk High
$3.80
52-wk Low
$0.18

LPTN.OQ

Chart for LPTN.OQ

About

Lpath, Inc. is a biotechnology company. The Company is focused on the discovery and development of lipidomic-based therapeutic antibodies. The Company has three product candidates, which include iSONEP, ASONEP and Lpathomab. The Company utilizes ImmuneY2 technology for the production of its antibodies. iSONEP is the ocular... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $6.22
Shares Outstanding(Mil.): 29.40
Dividend: --
Yield (%): --

Financials

  LPTN.OQ Industry Sector
P/E (TTM): -- 60.09 34.00
EPS (TTM): -0.79 -- --
ROI: -108.29 0.02 14.57
ROE: -115.70 -0.16 15.46
Search Stocks

Lpath to cut jobs as eye drug fails mid-stage study; shares fall

- Drug developer Lpath Inc said it would cut jobs and costs after its experimental eye drug failed a mid-stage study in patients with wet age-related macular degeneration, a leading cause of blindness in the elderly.

20 May 2015

UPDATE 1-Lpath to cut jobs as eye drug fails mid-stage study; shares fall

May 20 - Drug developer Lpath Inc said it would cut jobs and costs after its experimental eye drug failed a mid-stage study in patients with wet age-related macular degeneration, a leading cause of blindness in the elderly.

20 May 2015

Lpath to cut jobs as eye drug fails mid-stage study

May 20 - Lpath Inc said it would reduce its workforce and cut costs as its experimental drug failed a mid-stage study in patients with wet age-related macular degeneration, a leading cause of blindness in the elderly.

20 May 2015

Lpath's kidney cancer drug fails mid-stage trial

- Drug developer Lpath Inc said its experimental drug to treat renal cell carcinoma, the most common form of kidney cancer, failed to meet its main goal in a mid-stage trial.

24 Mar 2015

UPDATE 1-Lpath's kidney cancer drug fails mid-stage trial

March 24 - Drug developer Lpath Inc said its experimental drug to treat renal cell carcinoma, the most common form of kidney cancer, failed to meet its main goal in a mid-stage trial.

24 Mar 2015

Lpath's kidney cancer drug fails mid-stage trial

March 24 - Drug developer Lpath Inc said its experimental drug to treat renal cell carcinoma, the most common form of kidney cancer, failed in a mid-stage trial.

24 Mar 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Wright Reports
$75.00
Provider : Pechala's Reports
$15.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks